PagnatoKarp Partners LLC Purchases 80 Shares of GlaxoSmithKline PLC (GSK)
PagnatoKarp Partners LLC grew its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 1.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,812 shares of the pharmaceutical company’s stock after buying an additional 80 shares during the period. PagnatoKarp Partners LLC’s holdings in GlaxoSmithKline PLC were worth $253,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Bingham Osborn & Scarborough LLC bought a new position in GlaxoSmithKline PLC during the 2nd quarter worth $311,000. 10 15 Associates Inc. increased its position in GlaxoSmithKline PLC by 6.4% during the 1st quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after buying an additional 14,247 shares during the period. Lincluden Management Ltd. increased its position in GlaxoSmithKline PLC by 1.7% during the 1st quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares during the period. Anchor Capital Advisors LLC increased its position in GlaxoSmithKline PLC by 9.6% during the 1st quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares during the period. Finally, BlueCrest Capital Management Ltd increased its position in GlaxoSmithKline PLC by 293.5% during the 1st quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock worth $2,157,000 after buying an additional 38,157 shares during the period. Hedge funds and other institutional investors own 9.28% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “PagnatoKarp Partners LLC Purchases 80 Shares of GlaxoSmithKline PLC (GSK)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/20/pagnatokarp-partners-llc-purchases-80-shares-of-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline PLC (NYSE GSK) traded up 0.113% during mid-day trading on Wednesday, reaching $39.965. The company had a trading volume of 994,375 shares. The stock has a market capitalization of $97.67 billion, a P/E ratio of 39.491 and a beta of 1.03. The stock has a 50 day moving average price of $39.76 and a 200-day moving average price of $41.75. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.54.
GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities analysts anticipate that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be paid a $0.491 dividend. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a yield of 4.92%. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is currently 197.00%.
Several research analysts have weighed in on the company. Citigroup Inc. cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday, May 31st. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, TheStreet cut GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. GlaxoSmithKline PLC currently has an average rating of “Hold” and an average price target of $46.00.
GlaxoSmithKline PLC Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).
Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.